Isoniazid monotherapy for tuberculosis prevention during pregnancy and adverse outcomes in women living with HIV in Uganda: A propensity score–weighted analysis of routine care data
8 affiliations
- 1Infectious Diseases Institute, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda
- 2Global Health Institute, Faculty of Medicine and Health Science, University of Antwerp, Antwerp, Belgium
- 3School of Medicine, University of St Andrews, St Andrews, Scotland, United Kingdom
- 4National Tuberculosis and Leprosy Program, Uganda Ministry of Health, Kampala, Uganda
- 5Department of Disease Control, LSHTM, London, United Kingdom
- 6VIBRANIUM RESOURCES Foundation, Addis Ababa, Ethiopia
- 7Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
- 8Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden
Abstract
Data on the safety of tuberculosis preventive treatment (TPT) during pregnancy particularly from routine care settings in high tuberculosis (TB) burden countries remain limited. We evaluated the association between TPT exposure during pregnancy and adverse pregnancy outcomes among pregnant women living with HIV (WLHIV) in Uganda. We conducted a retrospective cohort study using routinely collected data from five public urban primary health facilities in Kampala, Uganda. We included pregnant women living with HIV on antiretroviral therapy (ART) between 2016 and 2022. The primary outcome was a composite of adverse pregnancy outcomes: miscarriage, stillbirth, low birth weight, neonatal complications, or maternal/neonatal death. A secondary composite outcome excluded neonatal and maternal death. There was no preterm delivery documented in this sample. The primary exposure was 6-month isoniazid preventive therapy (IPT) during pregnancy. We applied inverse probability of treatment weighting (IPTW) using propensity scores from logistic regression to adjust for confounding. Missing data on covariates and outcome were addressed using multiple imputation. Analysis was performed using R software v.4.3.3. We analyzed data from 521 pregnant WLHIV, the median age was 28 years (interquartile range 24–31), 44% of whom received IPT during pregnancy. Overall, 10.0% experienced an adverse pregnancy outcome. No significant differences were observed between IPT-exposed and unexposed groups for the primary (10.3% vs. 9.6%; p = 0.81) or secondary (10.3% vs. 8.5%; p = 0.50) composite outcomes. IPTW-adjusted analysis showed no significant association between IPT exposure and adverse pregnancy outcomes (weighted OR: 1.06; 95% CI: 0.68–1.63; p = 0.81). Sensitivity and subgroup analyses yielded consistent findings. Exposure to 6-month isoniazid TPT during pregnancy was not statistically associated with adverse pregnancy outcomes among women on ART in routine care settings. Strengthened pharmacovigilance and systematic clinical reporting are essential to ensure maternal and neonatal safety as TPT coverage expands in high TB/HIV burden settings.
Related
- Dynamic closure of the Mycobacterium tuberculosis InhA cofactor site reveals heterogeneous routes to isoniazid resistance
- Maternal gut microbiota, tryptophan metabolism and immune homeostasis: Implications for the prevention of adverse pregnancy complications
- Ravulizumab monotherapy for anti-CFH antibody-associated aHUS in an elderly patient: a case report highlighting individualized clinical decision-making
- Pregabalin Monotherapy for Chronic Pain Associated with Osteoarthritis in Working Dogs: A Retrospective Study of 21 Cases
- Maftivimab monotherapy is effective in a non-human primate model of Bundibugyo virus disease
BibTeX
@article{musaazi2026isoniazid,
title = {{Isoniazid monotherapy for tuberculosis prevention during pregnancy and adverse outcomes in women living with HIV in Uganda: A propensity score–weighted analysis of routine care data}},
author = {Joseph Musaazi and Christine Sekaggya-Wiltshire and Stella Zawedde-Muyanja and Proscovia M. Namuwenge and M. Sanni Ali and Yukari C. Manabe and Barbara Castelnuovo and Nele Brusselaers},
journal = {PLOS Global Public Health},
year = {2026},
month = sep,
doi = {10.1371/journal.pgph.0005829},
url = {https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0005829},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Isoniazid monotherapy for tuberculosis prevention during pregnancy and adverse outcomes in women living with HIV in Uganda: A propensity score–weighted analysis of routine care data
AU - Joseph Musaazi
AU - Christine Sekaggya-Wiltshire
AU - Stella Zawedde-Muyanja
AU - Proscovia M. Namuwenge
AU - M. Sanni Ali
AU - Yukari C. Manabe
AU - Barbara Castelnuovo
AU - Nele Brusselaers
PY - 2026
DA - 2026/09/25
JO - PLOS Global Public Health
DO - 10.1371/journal.pgph.0005829
UR - https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0005829
AB - Data on the safety of tuberculosis preventive treatment (TPT) during pregnancy particularly from routine care settings in high tuberculosis (TB) burden countries remain limited. We evaluated the association between TPT exposure during pregnancy and adverse pregnancy outcomes among pregnant women living with HIV (WLHIV) in Uganda. We conducted a retrospective cohort study using routinely collected data from five public urban primary health facilities in Kampala, Uganda. We included pregnant women living with HIV on antiretroviral therapy (ART) between 2016 and 2022. The primary outcome was a composite of adverse pregnancy outcomes: miscarriage, stillbirth, low birth weight, neonatal complications, or maternal/neonatal death. A secondary composite outcome excluded neonatal and maternal death. There was no preterm delivery documented in this sample. The primary exposure was 6-month isoniazid preventive therapy (IPT) during pregnancy. We applied inverse probability of treatment weighting (IPTW) using propensity scores from logistic regression to adjust for confounding. Missing data on covariates and outcome were addressed using multiple imputation. Analysis was performed using R software v.4.3.3. We analyzed data from 521 pregnant WLHIV, the median age was 28 years (interquartile range 24–31), 44% of whom received IPT during pregnancy. Overall, 10.0% experienced an adverse pregnancy outcome. No significant differences were observed between IPT-exposed and unexposed groups for the primary (10.3% vs. 9.6%; p = 0.81) or secondary (10.3% vs. 8.5%; p = 0.50) composite outcomes. IPTW-adjusted analysis showed no significant association between IPT exposure and adverse pregnancy outcomes (weighted OR: 1.06; 95% CI: 0.68–1.63; p = 0.81). Sensitivity and subgroup analyses yielded consistent findings. Exposure to 6-month isoniazid TPT during pregnancy was not statistically associated with adverse pregnancy outcomes among women on ART in routine care settings. Strengthened pharmacovigilance and systematic clinical reporting are essential to ensure maternal and neonatal safety as TPT coverage expands in high TB/HIV burden settings.
SN - 2767-3375
ER -